SA
FULC icon

Sanctuary Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Sanctuary Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,154
Closed -$121K – 2472
2025
Q3 		$121K Buy
+13,154
New +$95.2K ﹤0.01% 2327

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sanctuary Advisors's FULC Position: Q4 2025 in Review

Sanctuary Advisors sold out of Fulcrum Therapeutics (FULC) in Q4 2025, closing a stake of 13,154 shares — an estimated $121K sold.

Sanctuary Advisors first reported a position in FULC in Q3 2025 and held it in 1 quarter. The position peaked at $121K in Q3 2025. 172 funds tracked by Wall St. Rank hold FULC as of Q4 2025.

  • Sanctuary Advisors reported no remaining Fulcrum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sanctuary Advisors sold 13,154 Fulcrum Therapeutics shares in Q4 2025, an estimated $121K.
  • Sanctuary Advisors first reported a position in Fulcrum Therapeutics in Q3 2025 and held it in 1 quarter.
  • Sanctuary Advisors's Fulcrum Therapeutics position peaked at $121K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2025.

Based on Sanctuary Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.